|
US2015352195A1
|
|
Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
|
|
US2015223747A1
|
|
Patient reported outcome instrument
|
|
US2015197738A1
|
|
Acid Stable Prolyl Endopeptidases for Degrading Gluten
|
|
WO2013016427A1
|
|
Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
|
|
WO2012174127A1
|
|
Proteases for degrading gluten
|
|
WO2012135646A2
|
|
Proteases for degrading gluten
|
|
WO2011126873A2
|
|
Proteases for degrading gluten
|
|
EP2344183A1
|
|
Dosage forms that facilitate rapid activation of zymogen
|
|
NZ591025A
|
|
Formulation for oral administration of proteins
|
|
WO2007050795A2
|
|
Transglutaminase inhibitors and methods of use thereof
|
|
WO2007047303A2
|
|
Pegylated glutenase polypeptides
|
|
WO2007044906A2
|
|
Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
|
